A Phase 1/2a, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BJT-778 in Healthy Volunteers and in Subjects with Chronic Hepatitis B Infection, Including Subjects with Chronic Hepatitis D Infection - BJT-778-001
Latest Information Update: 04 Sep 2025
At a glance
- Drugs Brelovitug (Primary) ; Sodium chloride
- Indications Hepatitis B; Hepatitis D
- Focus Adverse reactions
- Sponsors Bluejay Therapeutics
Most Recent Events
- 04 Sep 2025 Planned End Date changed to 1 Jan 2025.
- 04 Sep 2025 Planned initiation date changed to 1 Jun 2023.
- 04 Sep 2025 Planned number of patients changed to 84.